Susquehanna International Group
KLRS

Susquehanna International Group’s Kalaris Therapeutics KLRS Stock Holding History

Susquehanna International Group’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$304K Buy
52,684
+39,828
+310% +$353K ﹤0.01% 10819
2025
Q4 		$109K Buy
+12,856
New +$82.2K ﹤0.01% 11410
2025
Q2 		– Sell
-13,796
Closed -$111K – 14001
2025
Q1 		$111K Buy
13,796
+10,153
+279% +$99.4K ﹤0.01% 11473
2024
Q4 		$35.2K Buy
3,643
+2,460
+208% +$37.2K ﹤0.01% 11801
2024
Q3 		$22K Sell
1,183
-6,126
-84% -$107K ﹤0.01% 11610
2024
Q2 		$122K Buy
7,309
+3,322
+83% +$58.6K ﹤0.01% 10881
2024
Q1 		$69.2K Buy
3,987
+2,426
+155% +$39.6K ﹤0.01% 11417
2023
Q4 		$24.4K Sell
1,561
-4,384
-74% -$173K ﹤0.01% 11932
2023
Q3 		$294K Buy
5,945
+4,912
+476% +$335K ﹤0.01% 9389
2023
Q2 		$80.8K Buy
1,033
+308
+42% +$29.3K ﹤0.01% 11102
2023
Q1 		$65.7K Buy
+725
New +$92.3K ﹤0.01% 11564
2022
Q4 		– Sell
-1,449
Closed -$263K – 13920
2022
Q3 		$263K Buy
1,449
+432
+42% +$67.3K ﹤0.01% 10133
2022
Q2 		$91K Sell
1,017
-85
-8% -$8.91K ﹤0.01% 11555
2022
Q1 		$171K Sell
1,102
-93
-8% -$18.6K ﹤0.01% 11428
2021
Q4 		$356K Buy
1,195
+314
+36% +$146K ﹤0.01% 10076
2021
Q3 		$508K Sell
881
-414
-32% -$192K ﹤0.01% 9362
2021
Q2 		$588K Sell
1,295
-1,815
-58% -$937K ﹤0.01% 9207
2021
Q1 		$1.67M Buy
3,110
+2,554
+459% +$2.15M ﹤0.01% 6351
2020
Q4 		$491K Buy
+556
New +$428K ﹤0.01% 8334

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Susquehanna International Group's KLRS Position: Q1 2026 in Review

Susquehanna International Group increased its Kalaris Therapeutics (KLRS) stake by 310% in Q1 2026, buying an estimated $353K and bringing the position to 52,684 shares worth $304K. The position accounts for ﹤0.01% of the portfolio, ranked #10819.

Susquehanna International Group first reported a position in KLRS in Q4 2020 and has held it in 19 quarters since. The position peaked at $1.67M in Q1 2021. 58 funds tracked by Wall St. Rank hold KLRS as of Q1 2026.

  • Susquehanna International Group held 52,684 shares of Kalaris Therapeutics worth $304K as of Q1 2026.
  • Susquehanna International Group bought 39,828 Kalaris Therapeutics shares in Q1 2026, an estimated $353K.
  • Kalaris Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #10819 holding.
  • Susquehanna International Group first reported a position in Kalaris Therapeutics in Q4 2020 and has held it in 19 quarters since.
  • Susquehanna International Group's Kalaris Therapeutics position peaked at $1.67M in Q1 2021.
  • 58 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.